Stockscreener 앱 받기
0.2445
5.83%
0.0135
Virpax Pharmaceuticals Inc 주식(VRPX)의 최신 뉴스
Best Nanotechnology Stocks To Follow Today – May 31st - Defense World
Virpax Pharmaceuticals (NASDAQ:VRPX) Trading 4.4% Higher – Still a Buy? - Defense World
Virpax Pharmaceuticals appoints new independent director - MSN
Virpax and Nanomerics Enter Technology License Agreement for Developing A Product for PTSD Treatment - StatNano
Promising Nanotechnology Stocks To Watch Now – May 7th - The AM Reporter
Virpax Pharmaceuticals (NASDAQ:VRPX) Trading Up 5.5% – Here’s What Happened - Defense World
Virpax(R) Pharmaceuticals Announces Appointment of Michèle C. Linde, EVP, General Counsel - ACCESS Newswire
Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) Sees Large Increase in Short Interest - Defense World
Virpax Pharmaceuticals to Present NES100 Toxicity Study at Major Toxicology Conference - MSN
Virpax Pharmaceuticals to be delisted from Nasdaq By Investing.com - Investing.com South Africa
Virpax Pharmaceuticals stock plummets on Nasdaq delisting news By Investing.com - Investing.com South Africa
Virpax Pharmaceuticals stock plummets on Nasdaq delisting news - Investing.com India
Virpax Pharmaceuticals to be delisted from Nasdaq - Investing.com
Promising Nanotechnology Stocks To ResearchMarch 29th - MarketBeat
Promising Nanotechnology Stocks To Watch NowMarch 22nd - MarketBeat
Virpax Pharmaceuticals enacts 1-for-25 reverse stock split By Investing.com - Investing.com Australia
Virpax Pharmaceuticals enacts 1-for-25 reverse stock split - Investing.com India
VRPX stock plunges to 52-week low of $0.12 amid market challenges - Investing.com Australia
Virpax Pharmaceuticals Announces the Formation of Novvae™ Pharmaceuticals - Business Wire
Virpax Pharmaceuticals announces 1-for-25 reverse stock split By Investing.com - Investing.com South Africa
VRPX stock plunges to 52-week low of $0.12 amid market challenges By Investing.com - Investing.com South Africa
Virpax Pharmaceuticals announces 1-for-25 reverse stock split - Investing.com India
Virpax Pharmaceuticals Announces Reverse Stock Split - Business Wire
Virpax Reports Positive Results From Dose Range Finding Study of Pain Relief Treatment in Beagle Dogs - MarketScreener
Virpax receives positive Probudur(TM) results for dose range study -March 18, 2025 at 05:34 pm EDT - Marketscreener.com
Virpax reports positive results in Probudur dog study By Investing.com - Investing.com Australia
Virpax reports positive results in Probudur dog study - Investing.com
Breakthrough: Virpax's 5-Day Pain Drug Passes Critical Safety Test - StockTitan
Virpax Pharmaceuticals Explores Intranasal mRNA Vaccine Delivery Using MET - MSN
Virpax Pharmaceuticals stock hits 52-week low at $0.18 By Investing.com - Investing.com Australia
Virpax Pharmaceuticals stock hits 52-week low at $0.18 - Investing.com
Nanotechnology Stocks To Follow Now – March 7th - Defense World
Virpax Looking To Use Met To Develop Intranasal Covid Vaccine -March 07, 2025 at 08:36 am EST - Marketscreener.com
Virpax Looking to Use MET to Develop Intranasal COVID Vaccine - The Bakersfield Californian
Could This Needle-Free COVID Vaccine Technology Transform Vaccine Delivery? - StockTitan
Virpax Pharmaceuticals Applauds Successful Trial of Molecular Envelope Technology - MSN
Can Virpax's Nasal Pain Treatment Solve the Opioid Addiction Problem? - StockTitan
Virpax’s NES100 to be Presented at The Society of Toxicology by NCATS - Business Wire
Stock Market Update – Virpax Pharmaceuticals Stock Price Prediction 2025 - ldccbank
1.21%
1.51%
자본화:
|
볼륨(24시간):